Toboroz
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
NCT03067181· 3. fázis· Children's Oncology Group· Forrás
Contact: John R. Hill
Fut, nem toboroz
Breast Cancer WEight Loss Study (BWEL Study)
NCT02750826· 3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Fut, nem toboroz
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
NCT02785952· 3. fázis· SWOG Cancer Research Network· Forrás
Fut, nem toboroz
Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery
NCT02506153· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
NCT02445391· 3. fázis· ECOG-ACRIN Cancer Research Group· Forrás
Fut, nem toboroz
Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
NCT02224781· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
NCT02488967· 3. fázis· NRG Oncology· Forrás
Fut, nem toboroz
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992· 3. fázis· ECOG-ACRIN Cancer Research Group· Forrás
Fut, nem toboroz
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT02048813· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia
NCT01886872· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
NCT01863550· 3. fázis· ECOG-ACRIN Cancer Research Group· Forrás
Fut, nem toboroz
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
NCT01841736· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma
NCT01856192· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
S0820, Adenoma and Second Primary Prevention Trial
NCT01349881· 3. fázis· SWOG Cancer Research Network· Forrás
Fut, nem toboroz
Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer
NCT01708954· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma
NCT01415752· 2. fázis· Eastern Cooperative Oncology Group· Forrás
Fut, nem toboroz
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
NCT01522976· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
NCT01274338· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
NCT01169337· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery
NCT01220583· 2. fázis· Radiation Therapy Oncology Group· Forrás
Fut, nem toboroz
Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer
NCT01081262· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
NCT00843882· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT00588770· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
NCT00644228· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
NCT00565851· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
NCT00569127· 3. fázis· National Cancer Institute (NCI)· Forrás